Company: BIAF
Filing Date: 2025-09-24
Form Type: S-1
Source: 0001493152-25-014730
Chunk: 52

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-09-24
Form: S-1
Chunk 52
---
, Inc.

Up to 729,927 Shares of Common Stock

Up to 1,094,891 September 2025 Warrants to Purchase Shares of Common Stock

Up to 729,927 Pre-Funded Warrants to Purchase Shares of Common Stock

Placement Agent Warrants to Purchase up to 21,898 Shares of Common Stock

Up to 1,846,716 Shares of Common Stock Underlying the September 2025 Warrants,

Pre-Funded Warrants and Placement Agent Warrants

PROSPECTUS

, 2025.</div>

<div align='center'>PART II - INFORMATION NOT REQUIRED IN PROSPECTUS</div>

Item 13. Other Expenses of Issuance and Distribution.

The following table sets forth an estimate of the fees and expenses relating to the issuance and distribution of the securities being registered hereby, other than underwriting discounts and commissions, all of which shall be borne by the registrant. All of such fees and expenses, except for the SEC registration fee and FINRA filing fee, are estimated:

| SEC               
 registration fee  |     | $ |   1,551 |
| FINRA             
 filing fee        |     | $ |   1,100 |
| Legal             
 fees and expenses |     | $ | 150,000 |
| Accounting        
 fees and expenses |     | $ |  25,000 |
| Miscellaneous     
 fees and expenses |     | $ |  28,349 |
| Total             |     | $ | 181,000 |

Item 14. Indemnification of Officers and Directors.

bioAffinity Technologies, Inc. is incorporated under the laws of the State of Delaware. Reference is made to Section 102(b)(7) of the DGCL, which enables a corporation in its original certificate of incorporation or an amendment thereto to eliminate or limit the personal liability of a director for violations of the director’s fiduciary duty, except (i) for any breach of the director’s duty of loyalty to the corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) pursuant to Section 174 of the DGCL, which provides for liability of directors for unlawful payments of dividends or unlawful stock purchase or redemptions, or (iv) for any transaction from which the director derived an improper personal benefit.

Section 145(a) of the DGCL provides, in general, that a corporation may indemnify any person